JP2020500178A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500178A5
JP2020500178A5 JP2019523671A JP2019523671A JP2020500178A5 JP 2020500178 A5 JP2020500178 A5 JP 2020500178A5 JP 2019523671 A JP2019523671 A JP 2019523671A JP 2019523671 A JP2019523671 A JP 2019523671A JP 2020500178 A5 JP2020500178 A5 JP 2020500178A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500178A (ja
JP7042468B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/061870 external-priority patent/WO2018093949A1/en
Publication of JP2020500178A publication Critical patent/JP2020500178A/ja
Publication of JP2020500178A5 publication Critical patent/JP2020500178A5/ja
Application granted granted Critical
Publication of JP7042468B2 publication Critical patent/JP7042468B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523671A 2016-11-16 2017-11-15 Magl阻害剤 Active JP7042468B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423102P 2016-11-16 2016-11-16
US62/423,102 2016-11-16
PCT/US2017/061870 WO2018093949A1 (en) 2016-11-16 2017-11-15 Magl inhibitors

Publications (3)

Publication Number Publication Date
JP2020500178A JP2020500178A (ja) 2020-01-09
JP2020500178A5 true JP2020500178A5 (2) 2020-12-24
JP7042468B2 JP7042468B2 (ja) 2022-03-28

Family

ID=62145825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523671A Active JP7042468B2 (ja) 2016-11-16 2017-11-15 Magl阻害剤

Country Status (27)

Country Link
US (2) US11059822B2 (2)
EP (1) EP3541820B1 (2)
JP (1) JP7042468B2 (2)
KR (1) KR20190080935A (2)
CN (1) CN110267962B (2)
AU (1) AU2017361253B2 (2)
BR (1) BR112019009880A2 (2)
CA (1) CA3043617A1 (2)
CL (1) CL2019001336A1 (2)
CO (1) CO2019004945A2 (2)
CR (1) CR20190239A (2)
DO (1) DOP2019000118A (2)
EA (1) EA038150B1 (2)
EC (1) ECSP19034535A (2)
ES (1) ES2952582T3 (2)
IL (1) IL266547B (2)
JO (1) JOP20190107A1 (2)
MA (1) MA46855A (2)
MX (1) MX389627B (2)
NI (1) NI201900049A (2)
PE (1) PE20191145A1 (2)
PH (1) PH12019501079A1 (2)
RU (1) RU2019115784A (2)
TN (1) TN2019000149A1 (2)
UA (1) UA125523C2 (2)
WO (1) WO2018093949A1 (2)
ZA (1) ZA201903099B (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197192A1 (en) * 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
DK3541807T3 (da) 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
KR20190085046A (ko) 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
EA201992409A1 (ru) 2017-05-23 2020-03-23 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Ингибиторы magl на основе пиразола
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
AU2019304198A1 (en) * 2018-07-19 2021-02-04 Pfizer Inc. Heterocyclic spiro compounds as MAGL inhibitors
PE20211089A1 (es) 2018-08-13 2021-06-14 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
IL297470A (en) 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003002A (en) 1910-10-10 1911-09-12 Gustave J Martel Tire-patching device.
EP1368354A1 (en) 2001-03-07 2003-12-10 Pfizer Products Inc. Modulators of chemokine receptor activity
EP1948630A2 (en) 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト,インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CN102575076B (zh) 2009-09-29 2014-08-20 普立万公司 具有模拟金属或珠光外观的聚酯制品
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
CA2791672A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
CA2917050A1 (en) 2013-07-03 2015-01-08 Todd K. Jones Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
CU24442B1 (es) 2014-04-04 2019-09-04 X Rx Inc Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
ES2878041T3 (es) * 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
SG10202012002TA (en) 2015-05-11 2021-01-28 Lundbeck La Jolla Research Center Inc Methods of treating inflammation or neuropathic pain
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
US10519134B2 (en) 2015-11-20 2019-12-31 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EA036637B1 (ru) 2016-03-31 2020-12-02 Такеда Фармасьютикал Компани Лимитед Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
DK3541807T3 (da) 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
KR20190085046A (ko) 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
EP4335848A3 (en) 2017-03-13 2024-06-19 Lundbeck La Jolla Research Center, Inc. Dual magl and faah inhibitors
EA201992409A1 (ru) 2017-05-23 2020-03-23 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Ингибиторы magl на основе пиразола
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑

Similar Documents

Publication Publication Date Title
JP2020500178A5 (2)
JP2020532545A5 (2)
JP2019104748A5 (2)
RU2019116512A (ru) Ингибиторы magl
JP2018529650A5 (2)
RU2019115784A (ru) Ингибиторы magl
JP2018533593A5 (2)
JP2020529994A5 (2)
JP2020504707A5 (2)
JP2012092103A5 (2)
JP2021523200A5 (2)
RU2019116514A (ru) Ингибиторы magl
JP2010511721A5 (2)
JP2020530487A5 (2)
JP2017522277A5 (2)
JP2016518434A5 (2)
JP2018510139A5 (2)
JP2014533695A5 (2)
JP2019524883A5 (2)
RU2016150486A (ru) Ингибиторы бета-лактамазы
JP2016518328A5 (2)
JP2017523225A5 (2)
JP2014511876A5 (2)
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
JP2016509062A5 (2)